Category Archives: Pricing and Value

Generics and Pricing, Part II – A Drug, A Price and a Senator

Recently Merck announced a lowering of the price of Zocor (simvastatin) in a move that presumably will put their brand name drug in a competitive position vis a vis an upcoming generic product, just approved by the FDA.  This brought … Continue reading

Posted in Marketing, Pricing and Value | 1 Comment

Memorial Day and Anniversaries

Well, this week is bringing up a lot of memories for me.  Today I’m going to share some of them.  I already did this once, in a memoir called A Fragile Circle.  But a number of years have passed since … Continue reading

Posted in Pricing and Value | Comments Off on Memorial Day and Anniversaries

Clouds on the Horizon, Part III

Back on April 7, in the posting Clouds on the Horizon, Part I, I wrote about Medicare Part D and the impending donut hole. For those of you who don’t remember, or are new to the blog, the donut hole … Continue reading

Posted in Pharma Industry Image, Pricing and Value | Comments Off on Clouds on the Horizon, Part III

More on Generics, the Pipeline and Communications

There has been a lot of news about generics lately. There are approximately 75 brand name drugs scheduled to go off-patent over the course of the next two years.  Last week, the highly lucrative statins saw the first generic among … Continue reading

Posted in Pharma Industry Image, Pricing and Value | 3 Comments

Clouds on the Horizon, Part 2

On Friday, I discussed the fact that there are some clouds on the horizon for the image of the pharmaceutical industry as the Medicare Drug Benefit matures. Today, I’m looking further out on the horizon.  The Pharmaceutical Research and Manufacturers … Continue reading

Posted in Marketing, Pricing and Value | Comments Off on Clouds on the Horizon, Part 2